Morgan Stanley Has Lowered Expectations for Silence Therapeutics (NASDAQ:SLN) Stock Price

Silence Therapeutics (NASDAQ:SLN - Get Free Report) had its price objective lowered by equities researchers at Morgan Stanley from $49.00 to $45.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has an "overweight" rating on the stock.

A number of other analysts have also weighed in on SLN. William Blair reissued an "outperform" rating on shares of Silence Therapeutics in a research report on Tuesday, November 19th. BMO Capital Markets reduced their price objective on shares of Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating on the stock in a research report on Tuesday, March 4th. The Goldman Sachs Group reduced their price objective on shares of Silence Therapeutics from $6.00 to $4.00 and set a "sell" rating on the stock in a research report on Tuesday, March 4th. HC Wainwright reissued a "buy" rating and issued a $75.00 price objective on shares of Silence Therapeutics in a research report on Wednesday, January 29th. Finally, Chardan Capital reissued a "buy" rating and issued a $55.00 price objective on shares of Silence Therapeutics in a research report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $40.67.

Remove Ads

Silence Therapeutics Price Performance

Shares of NASDAQ SLN traded up $0.11 during mid-day trading on Wednesday, hitting $4.85. 197,333 shares of the company's stock traded hands, compared to its average volume of 307,544. The company's 50-day moving average is $5.40 and its two-hundred day moving average is $11.37. The company has a market capitalization of $145.16 million, a P/E ratio of -3.09 and a beta of 1.08. Silence Therapeutics has a 1 year low of $4.06 and a 1 year high of $27.72.

Hedge Funds Weigh In On Silence Therapeutics

A number of hedge funds have recently added to or reduced their stakes in SLN. JPMorgan Chase & Co. bought a new position in shares of Silence Therapeutics during the fourth quarter valued at approximately $26,000. GAMMA Investing LLC boosted its stake in shares of Silence Therapeutics by 609.2% during the fourth quarter. GAMMA Investing LLC now owns 6,092 shares of the company's stock valued at $42,000 after purchasing an additional 5,233 shares in the last quarter. Barclays PLC boosted its stake in shares of Silence Therapeutics by 83.8% during the fourth quarter. Barclays PLC now owns 6,126 shares of the company's stock valued at $42,000 after purchasing an additional 2,793 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in Silence Therapeutics during the fourth quarter valued at approximately $69,000. Finally, Virtus ETF Advisers LLC lifted its position in Silence Therapeutics by 130.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company's stock valued at $74,000 after acquiring an additional 6,098 shares during the last quarter. 98.73% of the stock is currently owned by institutional investors.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.